Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a pill make your blood deadly to malaria mosquitoes?

NCT ID NCT07758985

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests whether a single oral dose of lotilaner, a drug currently used in animals, can make human blood lethal to Anopheles gambiae mosquitoes, the main carriers of malaria. Healthy adults in Mali will receive either a low or high dose of lotilaner or a placebo, with or without a high-fat meal. Researchers will then feed mosquitoes on participants' blood to see how many survive, while also monitoring safety and how the drug behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lotilaner
What this could lead to
If successful, this could lead to a new way to reduce malaria transmission by making human blood temporarily lethal to mosquitoes.
What could go wrong
This is an early-phase trial with a small number of healthy volunteers, so safety and effectiveness are not yet established. The drug may not kill enough mosquitoes or may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female volunteers aged 18-55 years of age (inclusive) at the time of signing the Informed Consent. 2. Total body weight (BW) ≥50 kg, and a body mass index (BMI) of 18-32 kg/m2 (inclusive). 3. Residence within the study area. 4. Judged healthy based on a comprehensive clinical assessment, including a detailed medical history and full physical examination. 5. Axillary temperature \<37.0ºC without history of fever during the previous week. 6. Willingness to adhere to the requirement regarding the use of contraception, as per the study protocol 7. Willingness and ability to adhere to study requirements and to participate and communicate for the duration of the trial. 8. Agreement to provide current contact details Exclusion Criteria: 1. Evidence of clinically significant, gastrointestinal, cardiac, lung, hepatic, neurologic, psychiatric, rheumatologic, autoimmune, dermatologic, hematological, oncologic, or renal disease by anamnesis, physical examination, and/or laboratory tests. 2. Known Central Nervous System disorders or a history of seizures. 3. Any surgery that may affect drug bioavailability (excluding appendectomy and cholecystectomy). 4. Signs and symptoms of uncomplicated or severe malaria. An asymptomatic Plasmodium infection is not exclusionary. 5. Female who is lactating or pregnant according to the serum pregnancy test at Screening. 6. History of significant hypersensitivity to lotilaner (including excipients of the formulations) or any related products. 7. History of a severe allergic reaction or anaphylaxis or severe hypersensitivity reactions to any drugs. 8. Significant history of drug dependency or alcohol abuse (\>3 units of alcohol per day, intake of excessive alcohol, acute or chronic). 9. Participants who are current smokers or have used nicotine-containing products within 90 days prior to study treatment administration. 10. Severe asthma (defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past two years, or that has required the use of oral or parenteral corticosteroids at any time during the past two years). 11. Known asplenia or functional asplenia. 12. Known history or evidence of clinically significant cardiovascular abnormalities 13. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) 1 and 2 antibody results. 14. Known diabetes or diabetes identified during screening 15. Any serious medical condition or abnormality in clinical laboratory tests that, in the opinion of the investigator, precludes the Participant's safe participation in and completion of the study or affects the ability of the Participant to understand and comply with the study protocol. 16. Prior antimalarial therapy or antibiotics with antimalarial activity (prophylaxis or treatment) within four weeks or five half-lives (whichever is longer) before study drug administration. 17. Current or recent use of any prohibited medications according to the study protocol 18. Pre-planned surgery during the study. 19. Intake of lotilaner in the six months before the study drug administration. 20. Receipt of any investigational product within the past 30 days or five half-lives (whichever is longer) before screening. 21. Use of St. John's wort in the 28 days before study treatment administration and through the duration of the study. 22. Participation or planned participation in an interventional trial with an investigational product before the last required protocol visit. 23. Treatment with systemic ivermectin within four weeks or five half-lives (whichever is longer) before Screening. 24. Any individual who, in the judgment of an Investigator, is likely to be non-compliant during the trial, or is unable to cooperate. 25. Any individual who is an Investigator, research assistant, pharmacist, trial coordinator, or other staff thereof, directly involved in conducting the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malaria are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Malaria Research and Training Center

    Bamako, Mali

More trials for these conditions

Other studies related to the condition(s) this trial covers.